Tunneling Nanotubes Mediated microRNA-155 Intercellular Transportation Promotes Bladder Cancer Cells' Invasive and Proliferative Capacity

References

• Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323–334. doi:10.1038/nrc326122513401
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–271. doi:10.3322/caac.v64.424890451
   PubMed Web of Science ®Google Scholar
• Rustom A, Saffrich R, Markovic I, Walther P, Gerdes HH. Nanotubular highways for intercellular organelle transport. Science. 2004;303(5660):1007–1010. doi:10.1126/science.109313314963329
   PubMed Web of Science ®Google Scholar
• Guescini M, Leo G, Genedani S, et al. Microvesicle and tunneling nanotube mediated intercellular transfer of g-protein coupled receptors in cell cultures. Exp Cell Res. 2012;318(5):603–613. doi:10.1016/j.yexcr.2012.01.00522266577
   PubMed Web of Science ®Google Scholar
• Lou E, Fujisawa S, Morozov A, et al. Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma. PLoS One. 2012;7(3):e33093. doi:10.1371/journal.pone.003309322427958
   PubMed Web of Science ®Google Scholar
• Rolf HJ, Niebert S, Niebert M, Gaus L, Schliephake H, Wiese KG. Intercellular transport of Oct4 in mammalian cells: a basic principle to expand a stem cell niche? PLoS One. 2012;7(2):e32287. doi:10.1371/journal.pone.003228722359678
   PubMedGoogle Scholar
• Thayanithy V, Dickson EL, Steer C, Subramanian S, Lou E. Tumor-stromal cross talk: direct cell-to-cell transfer of oncogenic microRNAs via tunneling nanotubes. Transl Res. 2014;164(5):359–365. doi:10.1016/j.trsl.2014.05.01124929208
   PubMed Web of Science ®Google Scholar
• Lu J, Zheng X, Li F, et al. Tunneling nanotubes promote intercellular mitochondria transfer followed by increased invasiveness in bladder cancer cells. Oncotarget. 2017;8(9):15539–15552. doi:10.18632/oncotarget.1469528107184
   PubMedGoogle Scholar
• Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol. 2008;9(3):219–230. doi:10.1038/nrm234718270516
   PubMed Web of Science ®Google Scholar
• He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828–833. doi:10.1038/nature0355215944707
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103(7):2257–2261. doi:10.1073/pnas.051056510316461460
   PubMed Web of Science ®Google Scholar
• Catto JW, Miah S, Owen HC, et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009;69(21):8472–8481. doi:10.1158/0008-5472.CAN-09-074419843843
   PubMed Web of Science ®Google Scholar
• Ma L, Young J, Prabhala H, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010;12(3):247–256.20173740
   PubMed Web of Science ®Google Scholar
• Park SK, Park YS, Ahn JY, et al. MiR 21-5p as a predictor of recurrence in young gastric cancer patients. J Gastroenterol Hepatol. 2016;31(8):1429–143526824898
   PubMed Web of Science ®Google Scholar
• Forrest AR, Kanamori-Katayama M, Tomaru Y, et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia. 2010;24(2):460–466.19956200
   PubMed Web of Science ®Google Scholar
• Zhang KL, Zhou X, Han L, et al. MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab. Mol Cancer. 2014;13:63.24650032
   PubMed Web of Science ®Google Scholar
• Lin Z, Sun L, Chen W, et al. miR-639 regulates transforming growth factor beta-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting FOXC1. Cancer Sci. 2014;105(10):1288–1298.25130698
   PubMed Web of Science ®Google Scholar
• Sikand K, Singh J, Ebron JS, Shukla GC. Housekeeping gene selection advisory: glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and beta-actin are targets of miR-644a. PLoS One. 2012;7(10):e4751023091630
   PubMed Web of Science ®Google Scholar
• Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol. 2014;32(2):353–358.23266581
   PubMed Web of Science ®Google Scholar
• Port M, Glaesener S, Ruf C, et al. Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol Cancer. 2011;10:5221575166
   PubMed Web of Science ®Google Scholar
• Hromadnikova I, Kotlabova K, Ondrackova M, et al. Circulating C19MC microRNAs in preeclampsia, gestational hypertension, and fetal growth restriction. Mediators Inflamm. 2013;2013:186041.24347821
   PubMed Web of Science ®Google Scholar
• Ergun S, Tayeb TS, Arslan A, et al. The investigation of miR-221-3p and PAK1 gene expressions in breast cancer cell lines. Gene. 2015;555(2):377–381.25447917
   PubMed Web of Science ®Google Scholar
• Zhu FQ, Zeng L, Tang N, et al. MicroRNA-155 downregulation promotes cell cycle arrest and apoptosis in diffuse large B-Cell lymphoma. Oncol Res. 2016;24(6):415–427. doi:10.3727/096504016X1468503410347328281962
   PubMed Web of Science ®Google Scholar
• Catto JW, Alcaraz A, Bjartell AS, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59(5):671–681. doi:10.1016/j.eururo.2011.01.04421296484
   PubMed Web of Science ®Google Scholar
• Chen Z, Ma T, Huang C, Hu T, Li J. The pivotal role of microRNA-155 in the control of cancer. J Cell Physiol. 2014;229(5):545–550. doi:10.1002/jcp.v229.524122356
   PubMedGoogle Scholar
• Calame K. MicroRNA-155 function in B cells. Immunity. 2007;27(6):825–827. doi:10.1016/j.immuni.2007.11.01018093533
   PubMed Web of Science ®Google Scholar
• Wan G, Xie W, Liu Z, et al. Hypoxia-induced MIR155 is a potent autophagy inducer by targeting multiple players in the MTOR pathway. Autophagy. 2014;10(1):70–79. doi:10.4161/auto.2653424262949
   PubMed Web of Science ®Google Scholar
• Van Roosbroeck K, Fanini F, Setoyama T, et al. Combining Anti-Mir-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res. 2017;23(11):2891–2904. doi:10.1158/1078-0432.CCR-16-102527903673
   PubMed Web of Science ®Google Scholar
• Pai J, Hyun S, Hyun JY, et al. Screening of Pre-miRNA-155 binding peptides for apoptosis inducing activity using peptide microarrays. J Am Chem Soc. 2016;138(3):857–867. doi:10.1021/jacs.5b0921626771315
   PubMedGoogle Scholar
• Wang H, Men CP. Correlation of increased expression of MicroRNA-155 in bladder cancer and prognosis. Lab Med. 2015;46(2):118–122. doi:10.1309/LMWR9CEA2K2XVSOX25918190
   PubMedGoogle Scholar
• Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540–556. doi:10.1016/j.cell.2017.09.00728988769
   PubMed Web of Science ®Google Scholar
• Dunlop EA, Tee AR. Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal. 2009;21(6):827–835. doi:10.1016/j.cellsig.2009.01.01219166929
   PubMed Web of Science ®Google Scholar
• Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010;40(2):310–322. doi:10.1016/j.molcel.2010.09.02620965424
   PubMed Web of Science ®Google Scholar
• Aylett CH, Sauer E, Imseng S, et al. Architecture of human mTOR complex 1. Science. 2016;351(6268):48–52. doi:10.1126/science.aaa387026678875
   PubMed Web of Science ®Google Scholar
• Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137(5):873–886. doi:10.1016/j.cell.2009.03.04619446321
   PubMed Web of Science ®Google Scholar
• Caron A, Briscoe DM, Richard D, Laplante M. DEPTOR at the nexus of cancer, metabolism, and immunity. Physiol Rev. 2018;98(3):1765–1803. doi:10.1152/physrev.00064.201729897294
   PubMed Web of Science ®Google Scholar
• Alayev A, Salamon RS, Berger SM, et al. mTORC1 directly phosphorylates and activates ERalpha upon estrogen stimulation. Oncogene. 2016;35(27):3535–3543. doi:10.1038/onc.2015.41426522726
   PubMedGoogle Scholar
• Catena V, Fanciulli M. Deptor: not only a mTOR inhibitor. J Exp Clin Cancer Res. 2017;36(1):12. doi:10.1186/s13046-016-0484-y28086984
   PubMedGoogle Scholar
• Rogers-Broadway KR, Kumar J, Sisu C, et al. Differential expression of mTOR components in endometriosis and ovarian cancer: effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry. Int J Mol Med. 2019;43(1):47–56. doi:10.3892/ijmm.2018.396730387804
   PubMed Web of Science ®Google Scholar
• Martin EC, Rhodes LV, Elliott S, et al. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity. Mol Cancer. 2014;13:229. doi:10.1186/1476-4598-13-22925283550
   PubMedGoogle Scholar
• Jablonska E, Gorniak P, Prusisz W, et al. Downregulation of deptor by MiR-155 promotes cell survival through activation of PI3K/AKT and NFkB Signaling in ABC-type diffuse large B-Cell lymphomas. Blood. 2016;128(22):1761. doi:10.1182/blood.V128.22.1761.1761
   Web of Science ®Google Scholar
• Krishan S, Richardson DR, Sahni S. Adenosine monophosphate-activated kinase and its key role in catabolism: structure, regulation, biological activity, and pharmacological activation. Mol Pharmacol. 2015;87(3):363–377. doi:10.1124/mol.114.09581025422142
   PubMedGoogle Scholar